Tracers / [225Ac]Ac-225-PRIT
[225Ac]Ac-225-PRIT
Also written as Ac-225-PRIT
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 3
What it is
- Compound class
- DOTA-based small-molecule radiometal-chelating hapten (Proteus-DOTA) used in pretargeted radioimmunotherapy
- Target / mechanism
- Pretargeting via bispecific anti-HER2/anti-DOTA antibody (or anti-GPA33/anti-DOTA antibody) that binds tumor antigen then captures 225Ac-DOTA hapten PMID 40473462
- Clinical application
- Pretargeted alpha-radioimmunotherapy (PRIT) targeting HER2 or GPA33 for solid tumor xenografts (ovarian peritoneal carcinomatosis, breast cancer, colorectal cancer) PMID 40473462
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | — | Proteus-DOTA (Pr) | 40756357 2025 Theranostics Chemical synthesis of Pr and subsequent radiolabeling with [225Ac]Ac(NO3)3 yielding the [225Ac]Ac-Pr radioligand was performed according to previous methods |
| Manual synthesis | — | — | — | — | Proteus DOTA (Pr) | 40473462 2025 J Nucl Med General details regarding cell lines, PRIT reagents, and radiolabeling of Pr can be found in the supplemental materials |
| — | — | — | — | — | — | 37348919 2023 J Nucl Med |
Need this precursor?We can point you to suppliers for [225Ac]Ac-225-PRIT, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40756357: 'Proteus-DOTA (Pr), the precursor to the 111In and 225Ac-labeled radioligand, consists of a three-arm DOTA radiometal-chelating agent'. Stage set/updated at stage 23 from PMID 37348919: 'Here, we report the use of human epidermal growth factor receptor 2 (HER2) 225Ac-pretargeted radioimmunotherapy (PRIT) to treat a mouse model of human EOC SKOV3 xenografts growing as peritoneal carcinomatosis (PC).'.